Amplification of CyclinL1 in uterine cervical carcinoma has prognostic implications

Molecular Carcinogenesis

Volumn 49, Issue 11, 2010, Pages 935-943

  Mitra, Sraboni ^a   Mazumder Indra, Dipanjana ^a   Basu, Partha S ^a   Mondal, Ranajit K ^a   Roy, Anup ^b   Roychoudhury, Susanta ^c   Panda, Chinmay K ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b Midnapore Medical College and Hospital   (India)

^c INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Chromosome 3q; Cyclin L1; Overexpression; Radiotherapy

Indexed keywords

CYCLIN L1; CYCLINE; MESSENGER RNA; UNCLASSIFIED DRUG; CCNL1 PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CELL STRIAN SIHA; CERVICAL CARCINOGENESIS; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE SEVERITY; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE LOCUS; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HELA CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PARITY; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; RADIOSENSITIVITY; SEXUAL BEHAVIOR; UTERINE CERVIX CARCINOMA IN SITU; UTERUS CANCER; WESTERN BLOTTING; ADOLESCENT; CASE CONTROL STUDY; CHILD; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; GENE DOSAGE; GENETICS; METABOLISM; PATHOLOGY; SURVIVAL RATE; TUMOR CELL CULTURE; UTERINE CERVIX; UTERINE CERVIX TUMOR;

ADOLESCENT; ADULT; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; CHILD; CYCLINS; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IMMUNOENZYME TECHNIQUES; PROGNOSIS; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 78149302189     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20671     Document Type: Article

References (42)

1. Sen U, Sankaranarayanan R, Mandal S, Ramanakumar AV, Parkin DM, Siddiqi M. Cancer patterns in eastern India: The first report of the Kolkata cancer registry. Int J Cancer 2002; 100: 86-91.
2. zur Hausen H. Papilloma virus causing cancer: Evasion from host cell control in early events in carcinogenesis. J Natl Cancer Inst 2000; 91: 690-698.
3. Lazo PA. The molecular genetics of cervical carcinoma. Br J Cancer 1999; 80: 2008-2016.
4. Heselmeyer K, Schröck E, du Manoir S, et al. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci USA 1996; 93: 479-484.
5. Allen DG, White DJ, Hutchins AM, et al. Progressive genetic aberrations detected by comparative genomic hybridization in squamous cell cervical cancer. Br J Cancer 2000; 83: 1659-1663.
6. Harris CP, Lu XY, Narayan G, Singh B, Murty VV, Rao PH. Comprehensive molecular cytogenetic characterization of cervical cancer cell lines. Genes Chromosomes Cancer 2003; 36: 233-241.
7. Bertelsen BI, Steine SJ, Sandvei R, Molven A, Laerum OD. Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: Frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer 2006; 118: 1877-1883.
8. Narayan G, Bourdon V, Chaganti S, et al. Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: Identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer 2007; 46: 373-384.
9. Ma YY, Wei SJ, Lin YC, et al. PIK3CA as an oncogene in cervical cancer. Oncogene 2000; 9: 2739-2744.
10. López-Ferrer A, Alameda F, Barranco C, Garrido M, Bolós CD. MUC4 expression is increased in dysplastic cervical disorders. Hum Pathol 2001; 32: 1197-1202.
11. Heselmeyer-Haddad K, Sommerfeld K, White NM, et al. Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer. Am J Pathol 2005; 166: 1229-1238.
12. Andersson S, Wallin KL, Hellström AC, et al. Frequent gain of the human telomerase gene TERC at 3q26 in cervical adenocarcinomas. Br J Cancer 2006; 95: 331-338.
13. Goto T, Takano M, Sasa H, Tsuda H, Yamauchi K, Kikuchi Y. Clinical significance of immunocytochemistry for PIK3CA as a carcinogenesis-related marker on liquid-based cytology in cervical intraepithelial neoplasia. Oncol Rep 2006; 15: 387-391.
14. Redon R, Hussenet T, Bour G, et al. Amplicon mapping and transcriptional analysis pinpoint Cyclin 1 as a candidate oncogene in head and neck cancer. Can Res 2002; 62: 6211-6217.
15. Zhu J, Krainer AR. Pre-mRNA splicing in the absence of an SR protein RS domain. Genes Dev 2000; 14: 3166-3178.
16. Dickinson LA, Edgar AJ, Ehley J, Gottesfeld JM. Cyclin L is an RS domain protein involved in pre-mRNA splicing. J Biol Chem 2002; 277: 25465-25473.
17. Loyer P, Trembley JH, Grenet JA, et al. Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors influence of cyclin L isoforms on splice site selection. J Biol Chem 2008; 283: 7721-7732.
18. Berke JD, Sgambato V, Zhu PP, et al. Dopamine and glutamate induce distinct striatal splice forms of Ania-6, an RNA polymerase II-associated cyclin. Neuron 2001; 32: 174-176.
19. Iyer VR, Eisen MB, Ross DT, et al. The transcriptional program in the response of human fibroblasts to serum. Science 1999; 283: 83-87.
20. Satyanarayana A, Kaldis P. Mammalian cell-cycle regulation: Several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 2009; 28: 2925-2939.
21. Dasgupta S, Mukherjee N, Roy S, et al. Mapping of candidate tumor suppressor genes' loci on human chromosome 3 in head and neck squamous cell carcinoma of an Indian patient population. Oral Oncol 2002; 38: 6-15.
22. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: A laboratory manual, 2nd edition. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1989.
23. Dasgupta S, Chakraborty SB, Roy A, Roychowdhury S, Panda CK. Differential deletions of chromosome 3p are associated with the development of uterine cervical carcinoma in Indian patients. J Clin Pathol Mol Pathol 2003; 56: 263-269.
24. Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A, Collins VP. Deregulation of p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 2000; 60: 417-424.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods 2001; 25: 402-408.
26. Ferreira ID, Rosário VE, Cravo PVL. Real-time quantitative PCR with SYBR Green I detection for estimating copy numbers of nine drug resistance candidate genes in Plasmodium falciparum. Malaria J 2006; 5: 1.
27. T method. Nat Protoc 2008; 3: 1101-1108.
28. Ghosh S, Ghosh A, Maiti GP, et al. Alterations of ROBO1/DUTT1 and ROBO2 loci in early dysplastic lesions of head and neck: Clinical and prognostic implications. Hum Genet 2009; 125: 189-198.
29. Singh RK, Indra D, Mitra S, et al. Deletions in chromosome 4 differentially associated with the development of cervical cancer: Evidence of SLIT2 as a candidate tumor suppressor gene. Hum Genet 2007; 122: 71-81.
30. Singh RK, Dasgupta S, Bhattacharya N, et al. Deletion in chromosome 11 and Bcl-1/CyclinD1 alterations are independently associated with the development of uterine cervical carcinoma. J Cancer Res Clin Oncol 2005; 131: 395-406.
31. Muller D, Millon R, Théobald S, et al. Cyclin L1 (CCNL1) gene alterations in human head and neck squamous cell carcinoma. Br J Cancer 2006; 94: 1041-1044.
32. Miyamoto R, Uzawa N, Nagaoka S, Hirata Y, Amagasa T. Prognostic significance of cyclin D1 amplification and overexpression in oral squamous cell carcinomas. Oral Oncol 2003; 39: 610-618.
33. Nürnberg W, Artuc M, Nawrath M, et al. Human c-myb is expressed in cervical carcinomas and transactivates the HPV-16 promoter. Cancer Res 1995; 55: 4432-4437.
34. Yang N, Huang J, Greshock J, et al. Transcriptional regulation of PIK3CA oncogene by NFKB in ovarian cancer microenvironment. PLoS ONE 2008; 3: e1758.
35. Tian W, Liou H-C. RNAi-mediated c-rel silencing leads to apoptosis of B cell tumor cells and suppresses antigenic immune response in vivo. PLoS ONE 2009; 4: e5028.
36. Nabors LB, Gillespie GY, Harkins L, King PH. HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3' untranslated regions of cytokine and angiogenic factor mRNAs. Cancer Res 2001; 61: 2154-2161.
37. Sung-Jig L, Kim HJ, Kim JY, Kyeougmee P, Chul-Min L. Expression of HuR is associated with increased cyclooxygenase-2 expression in uterine cervical carcinoma. Int J Gynecol Pathol 2007; 26: 229-234.
38. Piriyapongsa J, King Jordan I. A family of human microRNA genes from miniature inverted-repeat transposable elements. PLoS ONE 2007; 2: e203.
39. Bertucci F, Salas S, Eysteries S, et al. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 2004; 23: 1377-1391.
40. Herrmann A, Fleischer K, Czajkowska H, Müller-Newen G, Becker W. Characterization of cyclin L1 as an immobile component of the splicing factor compartment. FASEB J 2007; 21: 3142-3152.
41. Sticht C, Hofele C, Flechtenmacher C, et al. Amplification of Cyclin L1 is associated with lymph node metastases in head and neck squamous cell carcinoma (HNSCC). Br J Cancer 2005; 92: 770-774.
42. Gupta AK, Bakanauskas VJ, Cerniglia GJ, et al. The Ras radiation resistance pathway. Cancer Res 2001; 61: 4278-4282.